[Immunotherapy in sepsis syndrome].
Schellekens
J F
JF
Rijksinstituut voor Volksgezondheid en Milieuhygiëne, Bilthoven.
van Deventer
S J
SJ
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D016207:Cytokines / Q000037:antagonists & inhibitors; D004731:Endotoxins / Q000494:pharmacology; D006801:Humans; D007075:Immunoglobulin M / Q000627:therapeutic use; D007167:Immunotherapy / Q000379:methods*; D007375:Interleukin-1 / Q000037:antagonists & inhibitors; D008262:Macrophage Activation / Q000187:drug effects; D012772:Shock, Septic / Q000276:immunology / Q000628:therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D016207:Cytokines; D004731:Endotoxins; D007075:Immunoglobulin M; D007375:Interleukin-1; D014409:Tumor Necrosis Factor-alpha; C068069:nebacumab
Immuuntherapie van het sepsissyndroom.